A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Exclusion Criteria

• •Current bowel obstruction
• •Known brain metastases
• •Mean QTc \>470 msec (with Bazett's correction) in screening ECG or history of familial long QT syndrome.
• •Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •A New York Heart Association classification of III or IV requiring concurrent use of drugs or biologics with proarrhythmic potential.
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or cediranib
• •Unable to swallow orally administered medication and/or gastrointestinal disorders likely to interfere with absorption of the study medication.
• •Myelodysplastic syndrome/acute myeloid leukaemia
• •Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e.,hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.